Pathways towards an effective immunotherapy for Parkinson's disease

Jessica Al Hutter-Saunders, R Lee Mosley, Howard Eliot Gendelman

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Immunizations that target specific types of immune responses are used commonly to prevent microbial infections. However, a range of immune responses may prove necessary to combat the ravages of neurodegenerative diseases. The goal is to eliminate the 'root' cause of neurodegenerative disorders, misfolded aggregated proteins, while harnessing adaptive immune responses to promote neural repair. However, immunization strategies used to elicit humoral immune responses against aberrant brain proteins have yielded mixed success. While specific proteins can be cleared, the failures in halting disease progression revolve, in measure, around adaptive immune responses that promote autoreactive T cells and, as such, induce a meningoencephalitis, accelerating neurodegeneration. Thus, alternative approaches for protein clearance and neural repair are desired. To this end, our laboratories have sought to transform autoreactive adaptive immune responses into regulatory neuroprotective cells in Parkinson's disease. In this context, induction of immune responses against modified brain proteins serves to break immunological tolerance, while eliciting adaptive immunity to facilitate neuronal repair. How to harness the immune response in the setting of Parkinson's disease requires a thorough understanding of the role of immunity in human disease and the ways to modify such immune responses to elicit therapeutic gain. These are discussed in this review.

Original languageEnglish (US)
Pages (from-to)1703-1715
Number of pages13
JournalExpert Review of Neurotherapeutics
Volume11
Issue number12
DOIs
StatePublished - Dec 1 2011

Fingerprint

Immunotherapy
Parkinson Disease
Adaptive Immunity
Proteins
Neurodegenerative Diseases
Immunization
Meningoencephalitis
Brain
Humoral Immunity
Disease Progression
Immunity
T-Lymphocytes
Infection
Therapeutics

Keywords

  • Parkinson's disease
  • T cells
  • immunization
  • immunotherapy
  • neurodegeneration
  • regulatory T cells

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Pathways towards an effective immunotherapy for Parkinson's disease. / Hutter-Saunders, Jessica Al; Mosley, R Lee; Gendelman, Howard Eliot.

In: Expert Review of Neurotherapeutics, Vol. 11, No. 12, 01.12.2011, p. 1703-1715.

Research output: Contribution to journalReview article

@article{caaf4f4a63e74f5789573b30edc8de3e,
title = "Pathways towards an effective immunotherapy for Parkinson's disease",
abstract = "Immunizations that target specific types of immune responses are used commonly to prevent microbial infections. However, a range of immune responses may prove necessary to combat the ravages of neurodegenerative diseases. The goal is to eliminate the 'root' cause of neurodegenerative disorders, misfolded aggregated proteins, while harnessing adaptive immune responses to promote neural repair. However, immunization strategies used to elicit humoral immune responses against aberrant brain proteins have yielded mixed success. While specific proteins can be cleared, the failures in halting disease progression revolve, in measure, around adaptive immune responses that promote autoreactive T cells and, as such, induce a meningoencephalitis, accelerating neurodegeneration. Thus, alternative approaches for protein clearance and neural repair are desired. To this end, our laboratories have sought to transform autoreactive adaptive immune responses into regulatory neuroprotective cells in Parkinson's disease. In this context, induction of immune responses against modified brain proteins serves to break immunological tolerance, while eliciting adaptive immunity to facilitate neuronal repair. How to harness the immune response in the setting of Parkinson's disease requires a thorough understanding of the role of immunity in human disease and the ways to modify such immune responses to elicit therapeutic gain. These are discussed in this review.",
keywords = "Parkinson's disease, T cells, immunization, immunotherapy, neurodegeneration, regulatory T cells",
author = "Hutter-Saunders, {Jessica Al} and Mosley, {R Lee} and Gendelman, {Howard Eliot}",
year = "2011",
month = "12",
day = "1",
doi = "10.1586/ern.11.163",
language = "English (US)",
volume = "11",
pages = "1703--1715",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Pathways towards an effective immunotherapy for Parkinson's disease

AU - Hutter-Saunders, Jessica Al

AU - Mosley, R Lee

AU - Gendelman, Howard Eliot

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Immunizations that target specific types of immune responses are used commonly to prevent microbial infections. However, a range of immune responses may prove necessary to combat the ravages of neurodegenerative diseases. The goal is to eliminate the 'root' cause of neurodegenerative disorders, misfolded aggregated proteins, while harnessing adaptive immune responses to promote neural repair. However, immunization strategies used to elicit humoral immune responses against aberrant brain proteins have yielded mixed success. While specific proteins can be cleared, the failures in halting disease progression revolve, in measure, around adaptive immune responses that promote autoreactive T cells and, as such, induce a meningoencephalitis, accelerating neurodegeneration. Thus, alternative approaches for protein clearance and neural repair are desired. To this end, our laboratories have sought to transform autoreactive adaptive immune responses into regulatory neuroprotective cells in Parkinson's disease. In this context, induction of immune responses against modified brain proteins serves to break immunological tolerance, while eliciting adaptive immunity to facilitate neuronal repair. How to harness the immune response in the setting of Parkinson's disease requires a thorough understanding of the role of immunity in human disease and the ways to modify such immune responses to elicit therapeutic gain. These are discussed in this review.

AB - Immunizations that target specific types of immune responses are used commonly to prevent microbial infections. However, a range of immune responses may prove necessary to combat the ravages of neurodegenerative diseases. The goal is to eliminate the 'root' cause of neurodegenerative disorders, misfolded aggregated proteins, while harnessing adaptive immune responses to promote neural repair. However, immunization strategies used to elicit humoral immune responses against aberrant brain proteins have yielded mixed success. While specific proteins can be cleared, the failures in halting disease progression revolve, in measure, around adaptive immune responses that promote autoreactive T cells and, as such, induce a meningoencephalitis, accelerating neurodegeneration. Thus, alternative approaches for protein clearance and neural repair are desired. To this end, our laboratories have sought to transform autoreactive adaptive immune responses into regulatory neuroprotective cells in Parkinson's disease. In this context, induction of immune responses against modified brain proteins serves to break immunological tolerance, while eliciting adaptive immunity to facilitate neuronal repair. How to harness the immune response in the setting of Parkinson's disease requires a thorough understanding of the role of immunity in human disease and the ways to modify such immune responses to elicit therapeutic gain. These are discussed in this review.

KW - Parkinson's disease

KW - T cells

KW - immunization

KW - immunotherapy

KW - neurodegeneration

KW - regulatory T cells

UR - http://www.scopus.com/inward/record.url?scp=81755177485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81755177485&partnerID=8YFLogxK

U2 - 10.1586/ern.11.163

DO - 10.1586/ern.11.163

M3 - Review article

VL - 11

SP - 1703

EP - 1715

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 12

ER -